Mega Genomics Limited disclosed that it repurchased 108,400 ordinary shares on 21 July 2026 through on-market transactions on the Hong Kong Stock Exchange.

The shares were bought at prices ranging from HKD 6.98 to HKD 7.15, for a total consideration of HKD 0.78 million. Following the transaction:

• Issued shares (excluding treasury shares) declined by 0.0484% to 223.84 million. • Treasury shares increased to 458,600, bringing cumulative buybacks under the current mandate to 458,600 shares—0.2045% of the share base when the mandate was granted on 21 May 2026. • Total issued shares, including treasury shares, remain unchanged at 224.30 million.

Under Hong Kong listing rules, Mega Genomics is restricted from issuing new shares or disposing of treasury shares until 21 August 2026.

The board confirmed that the repurchase complied with all applicable regulations and the terms of the existing buyback mandate, which allows for the purchase of up to 22.43 million shares.